Company: BDRX
Filing Date: 2025-01-28
Form Type: 424B3
Source: 0001214659-25-001409
Chunk: 132

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-28
Form: 424B3
Chunk 132
---
 subject to suspension/delisting. We requested a hearing, which automatically stayed
any suspension or delisting action pending the hearing and the expiration of any additional extension period granted by the Panel following
the hearing.

On October 14, 2024, the Panel
granted our request for an extension of time to demonstrate compliance with the Minimum Bid Price Requirement. On November 7, 2024, we
were formally notified that the Panel determined that we had regained compliance with the Minimum Bid Price Requirement. We remain subject
to a discretionary panel monitor through February 24, 2025, and we are required to provide prompt notification during this exception period
of any significant events that occur during this time that may affect our compliance with NASDAQ requirements.

| 68 |

If, in the future, we fail
to sustain compliance with all applicable requirements for continued listing on NASDAQ, including during the one-year monitoring period,
our Depositary Shares may be subject to delisting by NASDAQ. This could inhibit the ability of our holders of Depositary Shares to trade
their shares in the open market, thereby severely limiting the liquidity of such shares, and the price of our Depositary Shares could
decline. Delisting may further impair our ability to raise capital.

In
our opinion, the environment for financing of small and micro-cap biotech companies continues to be challenging. While this may present
acquisition and/or merger opportunities with other companies with limited or no access to financing, as noted above, any attendant financings
by us are likely to be dilutive. We continue to evaluate financing options, including those connected to acquisitions and/or mergers,
potentially available to the Company. Any alternatives considered are contingent upon the agreement of counterparties and accordingly,
there can be no assurance that any of alternative courses of action to finance the Company would be successful. This requirement for additional
financing in the short term represents a material uncertainty that may cast significant doubt upon our ability to continue as a going
concern. Should it become evident in the future that there are no realistic financing options available to us which are actionable before
its cash resources run out then we will no longer be a going concern. In such circumstances, we would no longer be able to prepare financial
statements under paragraph 25 of IAS 1. Instead, the financial statements would be prepared on a liquidation basis and assets would be
stated at net realizable value and all liabilities would be accelerated to current liabilities.

As
noted herein,